Estimating the actual extent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging because virus test positivity data undercount the actual number and proportion of persons infected. SARS-CoV-2 seroprevalence is a marker of past SARS-CoV-2 infection regardless of presence or severity of symptoms and therefore is a robust biomarker of infection period prevalence. We estimated SARS-CoV-2 seroprevalence among residents of Hillsborough County, Florida, USA, to determine factors independently associated with SARS-CoV-2 antibody status overall and among asymptomatic antibody-positive persons. Among 867 participants, SARS-CoV-2 period prevalence (October 2020–March 2021) was 19.5% (asymptomatic seroprevalence was 8%). Seroprevalence was 2-fold higher than reported SARS-CoV-2 virus test positivity. Factors related to social distancing (e.g., essential worker status, not practicing social distancing, contact with a virus-positive person, and length of contact exposure time) were consistently associated with seroprevalence but did not differ by time since suspected or known infection (<6 months vs. > 6 months).
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses, SARS-CoV-2, Seroprevalence, Serosurvey, Seroepidemiologic studies, United States, vaccine-preventable diseases, Florida, Hillsborough County, 【초록키워드】 coronavirus, pandemic, Biomarker, social distancing, SARS-COV-2 infection, Infection, SARS-CoV-2 virus, virus, SARS-CoV-2 seroprevalence, SARS-CoV-2 antibody, Asymptomatic, USA, marker, Contact, acute respiratory syndrome, Factor, Participants, robust, period prevalence, not differ, proportion, reported, determine, severity of symptom, 【제목키워드】 USA, Period,